...
首页> 外文期刊>Indian heart journal >Blood pressure control and acceptability of Perindopril and its fixed dose combinations with Amlodipine or Indapamide, in younger patients with hypertension
【24h】

Blood pressure control and acceptability of Perindopril and its fixed dose combinations with Amlodipine or Indapamide, in younger patients with hypertension

机译:培哚普利及其与氨氯地平或吲达帕胺固定剂量联合用药在年轻高血压患者中的血压控制和可接受性

获取原文
           

摘要

Objective: Recent hypertension guidelines recommend initiation of treatment with a fixed dose combination of two drugs for more effective and quicker blood pressure control. Few of these have been assessed for efficacy and acceptability. This study examines the short term blood pressure control and acceptability of perindopril, with or without its fixed dose combinations (FDC) with amlodipine and Indapamide in younger patients. Methods: In a multicentre prospective observational study, patients with stage 1 hypertension were prescribed perindopril 4 mg per day. Those with stage 2 or 3 hypertension were prescribed a single tablet per day of 4 mg perindopril and 5 mg amlodipine (COVERSYL AM), or 4 mg perindopril and 1.25 mg indapamide (COVERSYL PLUS)for 45 days. The primary outcomes were the frequency of patients achieving blood pressure control and the adverse effect of pedal edema. Results: Of 426 patients, with a mean age of 45 years, distributed throughout India, and an average (SD) baseline systolic/diastolic blood pressure of 157.2 (13.5)/98.6 (7.4), 303 (71.1%) achieved blood pressure control. Mean (SD) SBP/DBP decreased from baseline by 26.9 (12.6), and DBP by 15.4 (7.2) mm Hg. Few patients discontinued treatment, and the frequency of cough that interfered with sleep and ankle edema was low. Conclusion: In patients requiring combination antihypertensive treatment, the regimen of perindopril alone or its FDC with Indapamide or amlodipine reduces blood pressure effectively, resulting in high rates of blood pressure control over the short term, with a low frequency of side effects including cough and pedal edema.
机译:目的:最新的高血压指南建议以两种药物的固定剂量组合开始治疗,以更有效,更快地控制血压。其中很少有人评估过疗效和可接受性。这项研究检查了年轻患者中培哚普利的短期血压控制和可接受性,以及是否有固定剂量组合(FDC)与氨氯地平和吲达帕胺联合使用。方法:在一项多中心前瞻性观察性研究中,患有1期高血压的患者每天服用培哚普利4 mg。患有2期或3期高血压的患者每天服用4片培哚普利和5毫克氨氯地平(COVERSYL AM)或4毫克培哚普利和1.25毫克吲达帕胺(COVERSYL PLUS)处方,持续45天。主要结果是控制血压的频率和踏板水肿的不良反应。结果:426名平均年龄为45岁的患者分布在印度各地,平均(SD)收缩压/舒张压的平均基线为157.2(13.5)/98.6(7.4),其中303名(71.1%)达到了血压控制。平均(SD)SBP / DBP从基线下降26.9(12.6)mmHg,而DBP下降15.4(7.2)mm Hg。很少有患者中止治疗,并且咳嗽的频率降低了睡眠和脚踝浮肿的发生率。结论:在需要联合降压治疗的患者中,单独使用培哚普利或其FDC联合吲达帕胺或氨氯地平可有效降低血压,从而在短期内可实现较高的血压控制率,并减少包括咳嗽和脚踏板的副作用浮肿。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号